Merck & Co. Inc.’s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer ...

In addition to the Phase 3 MK-3475A-D77 trial, Merck’s subcutaneous pembrolizumab clinical development program includes the ...

Merck's (MRK) new injectable version of Keytruda aims to overcome regulatory hurdles and market challenges, offering a more ...

US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...

Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion, recommending the approval of its ...

Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with ... The trial was funded by by a SU2C ...

adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...